UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma

Frontiers in immunology, 2023-10, Vol.14, p.1261257-1261257

2023

Volltextzugriff (PDF)

The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy

Cells (Basel, Switzerland), 2021-03, Vol.10 (3), p.607

2021

Volltextzugriff (PDF)

Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies

Cancers, 2021-05, Vol.13 (9), p.2225

2021

Volltextzugriff (PDF)

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

Journal for immunotherapy of cancer, 2022-09, Vol.10 (9), p.e005187

2022

Volltextzugriff (PDF)

Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models

Molecular imaging and biology, 2021-12, Vol.23 (6), p.914-928

2021

Volltextzugriff (PDF)

Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma

Clinical & translational immunology, 2019, Vol.8 (5), p.e1050-n/a

2019

Volltextzugriff (PDF)

Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma

Frontiers in immunology, 2022-04, Vol.13, p.850226-850226

2022

Volltextzugriff (PDF)

Correction to: Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models

Molecular imaging and biology, 2021, Vol.23 (6), p.929-929

2021

Volltextzugriff (PDF)

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Journal for immunotherapy of cancer, 2024-05, Vol.12 (5), p.e008659

2024

Volltextzugriff (PDF)

Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy

Clinical & translational immunology, 2020, Vol.9 (10), p.e1191-n/a

2020

Volltextzugriff (PDF)

Clinical chimeric antigen receptor T‐cell therapy: a new and promising treatment modality for glioblastoma

Clinical & translational immunology, 2021, Vol.10 (8), p.n/a

2021

Volltextzugriff (PDF)

Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma

Clinical & translational immunology, 2024-01, Vol.13 (7), p.e1519-n/a

2024

Volltextzugriff (PDF)

Abstract CT118: CARPETS: A Phase I study of the safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with GD2-positive metastatic melanoma and refractory solid tumors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT118-CT118

2019

Volltextzugriff (PDF)

A Poisson distribution-based general model of cancer rates and a cancer risk-dependent theory of aging

Aging (Albany, NY.), 2023-09, Vol.15 (17), p.8537-8551

2023

Volltextzugriff (PDF)

Robust, reversible gene knockdown using a single lentiviral short hairpin RNA vector

Human gene therapy, 2010-08, Vol.21 (8), p.1005

2010

Volltextzugriff (PDF)

Striking an alliance between T cells and macrophages for enhanced cancer immunotherapy

Immunology and cell biology, 2024-08, Vol.102 (7), p.535-537

2024

Volltextzugriff (PDF)

The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

Frontiers in pharmacology, 2014, Vol.5, p.235-235

2014

Volltextzugriff (PDF)

Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2

Cytotherapy (Oxford, England), 2015-04, Vol.17 (4), p.487-495

2015

Volltextzugriff (PDF)

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

Molecular therapy, 2016-06, Vol.24 (6), p.1135-1149

2016

Volltextzugriff (PDF)

Abstract 3159: In vitro characterization of third-generation chimeric antigen receptor T cells directed toward GD2-expressing and BRAF-inhibitor resistant melanoma target cells

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3159-3159

2015

Volltextzugriff (PDF)

Development of CD4+CD25+FoxP3+ regulatory T cells from cord blood hematopoietic progenitor cells

Journal of leukocyte biology, 2009-03, Vol.85 (3), p.445-451

2009

Volltextzugriff (PDF)

Abstract 3001: Investigating the quantity and quality of dendritic cells in human glioblastoma tissues and in orthotopic murine xenograft and syngraft models of glioblastoma

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3001-3001

2023

Volltextzugriff (PDF)

Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma

Cancer Immunology, Immunotherapy, 2018-09, Vol.67 (9), p.1461-1472

2018

Volltextzugriff (PDF)

Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype

Cytotherapy (Oxford, England), 2019-06, Vol.21 (6), p.593-602

2019

Volltextzugriff (PDF)

The inducible caspase-9 suicide gene system as a â€œsafety switchâ€ to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

Frontiers in pharmacology, 2014-10, Vol.5

2014

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(41)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma

The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy

Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models

Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma

Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma

Correction to: Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy

Clinical chimeric antigen receptor T‐cell therapy: a new and promising treatment modality for glioblastoma

Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma

Abstract CT118: CARPETS: A Phase I study of the safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with GD2-positive metastatic melanoma and refractory solid tumors

A Poisson distribution-based general model of cancer rates and a cancer risk-dependent theory of aging

Robust, reversible gene knockdown using a single lentiviral short hairpin RNA vector

Striking an alliance between T cells and macrophages for enhanced cancer immunotherapy

The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

Abstract 3159: In vitro characterization of third-generation chimeric antigen receptor T cells directed toward GD2-expressing and BRAF-inhibitor resistant melanoma target cells

Development of CD4+CD25+FoxP3+ regulatory T cells from cord blood hematopoietic progenitor cells

Abstract 3001: Investigating the quantity and quality of dendritic cells in human glioblastoma tissues and in orthotopic murine xenograft and syngraft models of glioblastoma

Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma

Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype

The inducible caspase-9 suicide gene system as a â€œsafety switchâ€ to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

Suchergebnisse filtern